Mr. Alan Simpson reports

PHARMACORP ANNOUNCES SUPPLEMENTAL LISTING OF WARRANTS

Pharmacorp Rx Inc. has received approval of the TSX Venture Exchange for the supplemental listing of 27,427,500 common share purchase warrants of the company issuable pursuant to the company's previously announced prospectus offering of units of the company. The warrants are expected to be listed for trading on the TSX-V, effective as of the opening of markets on Nov. 17, 2025, under the symbol PCRX.WT.

An aggregate of 54,855,000 units were issued in connection with the closing of the offering on Nov. 12, 2025, with each unit consisting of one common share in the capital of the company and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of 50 cents per warrant share at any time prior to 5 p.m. Calgary time on Nov. 12, 2027. The warrants are governed by a warrant indenture between the company and TSX Trust Company, as warrant agent, dated Nov. 12, 2025.

For more information about the offering and the warrants, please refer to the company's news release dated Nov. 12, 2025, and the warrant indenture, each of which is accessible under the company's profile on SEDAR+.

About Pharmacorp Rx Inc.

Pharmacorp is a Canadian pharmacy acquisition and ownership platform focused on empowering pharmacists as equity partners and supporting succession for retiring pharmacy owners. Through a combination of capital, strategic support and operational expertise, Pharmacorp is building a national network of community pharmacies under the Pharmachoice Canada banner. Pharmacorp currently operates seven Pharmachoice Canada bannered pharmacies and will continue to acquire both Pharmachoice Canada bannered and independent pharmacies across Canada, rebranding non-bannered locations under the Pharmachoice Canada platform in accordance with its strategic alliance with Pharmachoice Canada. Pharmacorp shares trade on the TSX Venture Exchange under the symbol PCRX.

Pharmacorp actively welcomes discussions with pharmacy owners considering succession or sale.

We seek Safe Harbor.